Quratis

Quratis EBITDA per Employee

The EBITDA per Employee of Quratis (348080.KQ) as of Oct 26, 2026 is -250.34 M KRW. In the previous year, EBITDA per Employee was -145.42 M KRW — a change of 72.14% (lower).

EBITDA per Employee

-250.34 MKRW

YoY

72.14%

Last updated:

EBITDA per Employee of Quratis is 2024 -250.34 M KRW. EBITDA per Employee of Quratis was 2023 -145.42 M KRW. It decreases by 72.14% lower compared to the previous year.

The Quratis EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2020
-145.14 M KRW
Jan 1, 2021
-156.12 M KRW
Jan 1, 2023
-145.42 M KRW
Jan 1, 2024
-250.34 M KRW
The Quratis EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-250.34 MKRW+72.14%
-145.42 MKRW-6.85%
-156.12 MKRW+7.57%
-145.14 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Quratis Stock analysis

What does Quratis do? Quratis, Inc. generates revenue through the manufacture and sale of vaccines, including tuberculosis vaccines for adults and adolescents and COVID-19 vaccines, as well as peptide nucleic acid complex products. The company provides Cell Penetrating Peptide (CPP) platform services to clients in the pharmaceutical sector. Revenue streams are derived from the development and research activities related to vaccine products, with a focus on tuberculosis and COVID-19 vaccine research for adult and adolescent populations. Quratis targets pharmaceutical companies and research institutions seeking advanced vaccine development solutions. The company's CPP platform services are utilized by clients requiring innovative delivery systems for therapeutic applications. Revenue is generated through direct sales of vaccine products and service contracts for CPP platform usage, primarily serving the pharmaceutical industry segment focused on vaccine development and research. The firm's primary products include tuberculosis vaccines for adults and adolescents, COVID-19 vaccines, and peptide nucleic acid complex. These products are sold to pharmaceutical companies and research organizations. The company's revenue model combines product sales with service-based offerings, where the Cell Penetrating Peptide (CPP) platform services represent a key revenue stream alongside vaccine sales. Quratis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quratis stock

EBITDA per Employee of Quratis is -250.34 M KRW in 2024.

EBITDA per Employee of Quratis changed from -145.42 M KRW to -250.34 M KRW, representing a 72.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Quratis since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Quratis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Quratis

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Quratis